PEGylated soluble tumor necrosis factor receptor I

Also Known As:

PEG sTNFRI; pegsunercept

Networked: 9 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Alcohols: 595
  - Glycols: 38
    - Ethylene Glycols: 8
      - Polyethylene Glycols: 3865
        PEGylated soluble tumor necrosis factor receptor I: 9
Macromolecular Substances: 97
- Polymers: 13051
  - Polyethylene Glycols: 3865
    - PEGylated soluble tumor necrosis factor receptor I: 9
Biomedical and Dental Materials
- Polymers: 13051
  - Polyethylene Glycols: 3865
    - PEGylated soluble tumor necrosis factor receptor I: 9
Technology, Industry, and Agriculture
- Manufactured Materials
  - Biomedical and Dental Materials
    - Polymers: 13051
      - Polyethylene Glycols: 3865
        PEGylated soluble tumor necrosis factor receptor I: 9
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Membrane Proteins: 10078
    - Cell Surface Receptors: 2125
      - Death Domain Receptors: 2368
        Type I Tumor Necrosis Factor Receptors: 1178
        PEGylated soluble tumor necrosis factor receptor I: 9
      - Immunologic Receptors: 9
        Cytokine Receptors: 1620
        Tumor Necrosis Factor Receptors: 3685
        Type I Tumor Necrosis Factor Receptors: 1178
        PEGylated soluble tumor necrosis factor receptor I: 9

Experts

1.	Graves, Dana T: 3 articles (01/2017 - 05/2008)
2.	Bolon, Brad: 2 articles (05/2005 - 10/2002)
3.	Feige, Ulrich: 2 articles (05/2005 - 10/2002)
4.	Alblowi, Jazia: 1 article (01/2017)
5.	Einhorn, Thomas A: 1 article (01/2017)
6.	Fang, Miao: 1 article (01/2017)
7.	Feinberg, Daniel: 1 article (01/2017)
8.	Gerstenfeld, Louis C: 1 article (01/2017)
9.	Kayal, Rayyan A: 1 article (01/2017)
10.	Ko, Kang I: 1 article (01/2017)

Related Diseases

1.	Inflammation (Inflammations) 05/01/2005 - "Paw swelling and synovial inflammation were significantly inhibited by PEG sTNFRI in AIA and CIA, and by IL-1Ra in CIA. " 10/01/2002 - "IL-1Ra, but not PEG sTNFRI, significantly reduced the number of capillaries in arthritic paws, even though both anticytokines reduced inflammation and bone erosion to a similar degree. " 10/01/2002 - "In a parallel study, male Lewis rats with mycobacteria-induced adjuvant-induced arthritis were treated with IL-1Ra or PEG sTNFRI for 7 days beginning at disease onset, after which scores for inflammation and bone erosion as well as capillary counts were acquired from sections of arthritic hind paws. " 01/01/2017 - "We examined fracture healing in normoglycemic and streptozotocin-induced diabetic mice and quantified the degree of angiogenesis with antibodies to three different vascular markers, CD34, CD31 and Factor VIII. The role of diabetes-enhanced inflammation was investigated by treatment of the TNFα-specific inhibitor, pegsunercept starting 10days after induction of fractures. "
2.	Arthritis (Polyarthritis) 10/01/2002 - "In a parallel study, male Lewis rats with mycobacteria-induced adjuvant-induced arthritis were treated with IL-1Ra or PEG sTNFRI for 7 days beginning at disease onset, after which scores for inflammation and bone erosion as well as capillary counts were acquired from sections of arthritic hind paws. " 12/01/2000 - "To determine the potential for additive or synergistic effects of combination therapy with the recombinant anticytokine agents interleukin-1 receptor antagonist (IL-1Ra) and PEGylated soluble tumor necrosis factor receptor type I (PEG sTNFRI) in established type H collagen-induced arthritis (CIA) and developing adjuvant-induced arthritis (AIA) in rats. " 05/01/2005 - "Lewis rats with either adjuvant-induced arthritis (AIA) or collagen-induced arthritis (CIA) were treated for 10 days with PEGylated soluble tumor necrosis factor receptor type I (PEG sTNFRI), interleukin-1 receptor antagonist (IL-1Ra), osteoprotegerin (OPG), parathyroid hormone (PTH), or combinations of these agents starting on day 4 after disease onset. "
3.	Rheumatoid Arthritis 12/01/2005 - "In a phase 2 study, to assess the efficacy and safety of pegsunercept, a soluble tumor necrosis factor receptor type I, for the treatment of rheumatoid arthritis (RA). "
4.	Body Weight (Weight, Body) 10/01/2006 - "PEG-sTNFRI administration increased body weight gain and adipose mass of arthritic rats; however, it did not modify the skeletal muscle weight. " 04/24/2006 - "The 8-day administration of PEG-sTNFRI resulted in an increase in food intake (P<0.05) and body weight gain (P<0.01) in arthritic but not in control rats. "
5.	Experimental Arthritis 12/01/2000 - "To determine the potential for additive or synergistic effects of combination therapy with the recombinant anticytokine agents interleukin-1 receptor antagonist (IL-1Ra) and PEGylated soluble tumor necrosis factor receptor type I (PEG sTNFRI) in established type H collagen-induced arthritis (CIA) and developing adjuvant-induced arthritis (AIA) in rats. " 05/01/2005 - "Lewis rats with either adjuvant-induced arthritis (AIA) or collagen-induced arthritis (CIA) were treated for 10 days with PEGylated soluble tumor necrosis factor receptor type I (PEG sTNFRI), interleukin-1 receptor antagonist (IL-1Ra), osteoprotegerin (OPG), parathyroid hormone (PTH), or combinations of these agents starting on day 4 after disease onset. "

Related Drugs and Biologics

1.	Type I Tumor Necrosis Factor Receptors
2.	Interleukin 1 Receptor Antagonist Protein (Anakinra)
3.	Interleukin-1 Receptors (Interleukin 1 Receptor)
4.	Osteoprotegerin
5.	Intercellular Signaling Peptides and Proteins (Growth Factors)
6.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
7.	Streptozocin (Streptozotocin)
8.	Parathyroid Hormone (Parathormone)
9.	Factor VIII (Coagulation Factor VIII)
10.	Antibodies

Related Therapies and Procedures

1.	Therapeutics